OA03-RF01.02. Clinical Significance of Endoscopic Sub-Classification “Remarkable Response (RR)” After Neoadjuvant DCF Therapy in Esophageal Squamous Cell Carcinoma

Clicks: 21
ID: 325989
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #145 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background In esophageal squamous cell carcinoma (ESCC), the importance of endoscopic assessment of tumor response after neoadjuvant chemotherapy has been reported. The Japanese Classification of Esophageal Cancer has introduced a new endoscopic sub-classification, “Remarkable response (RR),” but its clinical significance has not been fully clarified. Methods We retrospectively analyzed patients with resectable locally advanced ESCC (cT2–3/N0–3/M0–1, UICC-TNM 8th edition) who received ≥1 cycle of neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) therapy followed by surgery between 2015 and 2020 at our institution. Patients enrolled in JCOG1109, those without evaluable endoscopic images, those with >56 days from DCF completion to surgery, or those without R0 resection were excluded. Two endoscopists retrospectively evaluated pre- and post-treatment endoscopic images and classified cases into three groups: 1) non-CR/non-PD (RR), 2) non-CR/non-PD (non-RR) and 3) PD. Recurrence-free survival (RFS), overall survival (OS), and the proportion of histological responders (grade 2–3: moderately or markedly effective) were assessed. Results A total of 114 patients were included (median age 66.5 years, 91 mens). Endoscopic evaluation classified 63 patients as RR and 51 patients as non-RR, with no patients classified as PD. During a median follow-up of 42.6 months, 3-year RFS rates were 62.2% in the RR group and 49.0% in the non-RR group (P=0.098). Three-year OS rates were significantly higher in the RR group than in the non-RR group (76.9% vs. 53.0%, P=0.026). Histological responders (grade 2–3) was observed in 71.4% (45/63) of RR cases compared with 9.8% (5/51) of non-RR cases. Conclusion Endoscopic sub-classification “RR (Remarkable response)” may be useful for prognostic stratification and predicting histological response after neoadjuvant DCF therapy. We are planning multicenter studies with larger cohorts that include other treatment regimens, as well as chemoradiotherapy to further evaluate the clinical significance of RR.
Reference Key
openalex_W7204009330 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Takeaki Yamazaki, Tomohiro Kadota, Kazuma Sato, Hironori Sunakawa, Keiichiro Nakajo, Daisuke Kotani, Takashi Kojima, Shingo Sakashita, Takeo Fujita, Tomonori Yano
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.021
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.021/70760929/doag077.021.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.